BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOCRYST PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.07+0.28 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $2.14B
- P/E (TTM)
- –
- Dividend yield
- –
BIOCRYST PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $623.15M | $442.67M | $324.70M | $267.71M | $136.35M | $3.30M | $17.53M | – | $1.50M | $2.27M | 71.2% | +40.8% |
| ORLADEYO | $601.84M | $437.66M | $325.99M | $251.63M | $122.56M | – | – | – | – | – | 68.8% | +37.5% |
| License and other revenues | $251.69M | $8.04M | $6.72M | – | – | – | – | – | – | – | 28.8% | +3028.9% |
| License and other revenues | $243.98M | $0 | $0 | – | – | – | – | – | – | – | 27.9% | – |
| Other revenues | $29.02M | $13.05M | $5.42M | $19.19M | $34.62M | – | – | – | – | – | 3.3% | +122.3% |
| Collaborative and other revenues | $7.71M | $8.04M | $6.72M | $3.12M | $20.82M | $11.13M | $25.00M | $14.55M | $13.14M | $14.40M | 0.9% | -4.2% |
| Royalty | – | – | – | $2.90M | -$100.00K | $3.38M | $6.30M | $6.10M | $10.54M | $9.68M | – | – |
| Milestone | – | – | – | $0 | $15.00M | $0 | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Biocryst Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.